In order to identify genes or combination of genes that have the power to discriminate between premalignant Barrett's esophagus and Barrett's associated adenocarcinoma, we analysed a panel of 23 genes using quantitative real-time RT-PCR (qRT-PCR, Taqman s ) and bioinformatic tools. The genes chosen were either known to be associated with Barrett's carcinogenesis or were filtered from a previous cDNA microarray study on Barrett's adenocarcinoma. A total of 98 tissues, obtained from 19 patients with Barrett's esophagus (BE group) and 20 patients with Barrett's associated esophageal adenocarcinoma (EA group), were studied. Triplicate analysis for the full 23 gene of interest panel, and analysis of an internal control gene, was performed for all samples, for a total of more than 9016 single PCR reactions. We found distinct classes of gene expression patterns in the different types of tissues. The most informative genes clustered in six different classes and had significantly different expression levels in Barrett's esophagus tissues compared to adenocarcinoma tissues. Linear discriminant analysis (LDA) distinguished four genetically different groups. The normal squamous esophagus tissues from patients with BE or EA were not distinguishable from one another, but Barrett's esophagus tissues could be distinguished from adenocarcinoma tissues. Using the most informative genes, obtained from a logistic regression analysis, we were able to completely distinguish between benign Barrett's and Barrett's adenocarcinomas. This study provides the first non-array parallel mRNA quantitation analysis of a panel of genes in the Barrett's esophagus model of multistage carcinogenesis. Our results suggest that mRNA expression quantitation of a panel of genes can discriminate between premalignant and malignant Barrett's disease. Logistic regression and LDAs can be used to further identify, from the complete panel, gene subsets with the power to make these diagnostic distinctions. Expression analysis of a limited number of highly selected genes may have clinical usefulness for the treatment of patients with this disease.
Introduction
Barrett's esophagus is a condition in which metaplastic columnar epithelium replaces the normal stratified squamous epithelium of the esophagus as a complication of chronic gastroesophageal reflux. Barrett's esophagus is the precursor of esophageal adenocarcinoma, the incidence of which has been increasing rapidly in the United States and other western countries (Devesa et al., 1998) . Esophageal adenocarcinoma usually presents at an advanced stage and undergoes a rapidly fatal course, with 5-year survival rates of approximately 25-30% (Jemal et al., 2002) . It is hoped that the identification of biomarkers associated with each Barrett's stage and with an increased cancer risk will lead to earlier detection and improved survival for patients with this disease.
Recent advances in biotechnology have revolutionized the large-scale analysis of gene expression. In particular, the development of high-throughput quantitative real-time PCR (Gibson et al., 1996; Heid et al., 1996) and cDNA microarray technologies has made it possible to analyse simultaneously the expression of a large panel of genes. These techniques, in combination with advances in bioinformatics, promise more accurate disease classification, earlier detection, and higher efficiency in the field of cancer diagnosis (Perou et al., 2000; Virmani et al., 2002) . cDNA microarray studies of different cancer types including esophageal and other gastrointestinal cancers (Selaru et al., 2002a, b; Xu et al., 2002; Zou et al., 2002) have indicated the potential of a modern molecular taxonomy based on the statistical power of large phenotypic datasets. Direct analysis of cDNA microarrays generates precise ratios of gene expression, but it can be difficult to interpret this data. Moreover, certain bioinformatic methods, such as hierarchical clustering, have difficulty in recognizing subtle differences among predefined biological subgroups or identifying those genes which are most influential in these differences (Khan et al., 2001) .
We hypothesized that a valid molecular pathologic classification of Barrett's premalignant and malignant tissues could be obtained by applying the new methods of expression analysis used for microarray data to the analysis of a relatively large number of highly selected genes whose expression had been measured by qRT-PCR. Underlying this proposal is the assumption that the expression of some genes is significantly and reliably different at different stages of the Barrett's metaplasia, dysplasia, adenocarcinoma, multistage carcinogenesis model. The genes chosen for our panel either had reported associations with Barrett's carcinogenesis or were filtered from a previously performed Affymetrix s cDNA microarray study (Scherf et al., 2001) . The genes selected from the microarray data (BFT, TSPAN, SPARC, TM4SF3) were, of the more than 50 000 genes or ESTs analysed, among those most differentially expressed in normal esophagus and esophageal adenocarcinoma tissues. This study is the first to use this approach to construct a molecular profile of Barrett's esophagus and esophageal adenocarcinoma.
Results

Gene expression and the progression to adenocarcinoma of the esophagus
We analysed the mRNA expression status of a panel of 23 genes and one internal reference gene by quantitative real-time RT-PCR (qRT-PCR, TaqMan s ), performing more than 9016 separate PCR reactions. Table 1 shows the mRNA expression data for the 23 genes from our screen of 98 tissue specimens from 39 patients with different stages of Barrett's esophagus and/or adenocarcinoma. The alterations in mRNA expression of the genes are not uniform; they differ both in their pattern and their relative mRNA expression levels in various tissues. Accordingly, genes can be grouped by their expression behavior, as shown in Table 1 . We provide a rationale for each of the gene classes in the following section.
Of the 23 genes, the most informative genes were those with significantly different expression levels between Barrett's esophagus tissues from patients with a maximum diagnosis of Barrett's esophagus (Barrett's esophagus but no cancer, BE group) and Barrett's associated adenocarcinoma tissues from the cancer group (EA group). These genes were divided into three classes according to whether gene expression was progressively downregulated with progression from normal squamous esophagus through the metaplasia, dysplasia, adenocarcinoma stages of the Barrett's multistep process (class A), upregulated (class C), or followed an 'on-off' expression pattern (class F). The remaining genes were less different in different Barrett's tissues and were grouped into classes B, D, and E, as detailed below.
Class A consists of the genes BFT, GSTPI, RARg, and RXRa ( Table 1 ). The relative mRNA expression levels for BFT (Po0.001), RXRa (Po0.001), GSTPI (P ¼ 0.003), and RARg (P ¼ 0.035) were significantly lower in adenocarcinoma of the esophagus compared to Barrett's esophagus tissues from the BE group.
Class B consists of the genes COX1 and DPD. These genes have the highest expression in normal squamous esophagus tissue and are downregulated towards progression to adenocarcinoma of the esophagus, but the expression levels in Barrett's esophagus (BE group) and adenocarcinoma tissues (EA group) were not significantly different.
The Class C genes (COX2, DNMT3b, RARa, SPARC) have very low expression levels in normal squamous esophagus tissues and are progressively upregulated during progression to esophageal adenocarcinoma. Furthermore, these genes have significantly higher mRNA expression (COX2: P ¼ 0.003; RARa: P ¼ 0.009; DNMT3b: P ¼ 0.021; SPARC: Po0.001) in adenocarcinoma tissues compared to Barrett's tissues from the group of patients with no cancer (BE group).
Class D consists of the genes CDX2, C-myb, DNMT1, DNMT3a, ODC, and RXRg. These genes are generally upregulated with progression to adenocarcinoma but are not significantly differently expressed in Barrett's (BE group) and adenocarcinoma. Class F consists of the genes BAX, DAPK, RXRb, TM4SF3, and TSPAN. These genes follow an 'on-off' regulation during progression to cancer. Following upregulation of gene expression from normal esophagus to Barrett's esophagus (BE group), these genes (BAX: P ¼ 0.009; DAPK: P ¼ 0.005; RXRb: P ¼ 0.018; TM4SF3: P ¼ 0.028; TSPAN: Po0.001) are significantly downregulated between the histologies Barrett's esophagus and adenocarcinoma of the esophagus. Class E consists of only two genes, BCL2 and TP, with no significant alterations in gene expression between the different histologies of Barrett's disease.
Linear discriminant analysis (LDA)
To differentiate between histologies based on gene expression levels, a linear discriminant regression analysis was performed on the full data set. This analysis aims to find linear combinations of genes, the so-called linear discriminant vectors, which can discriminate between the different histologies. More formally, we let x ij denote the expression value of gene j on sample i. Suppose we have n samples and p genes, then we can denote the data for each sample by a vector 
The number of linear discriminant functions is at most equal to min{n, p}, and the functions are chosen in order to maximize the ratio of between-group to within-group sums of squares and cross-products. As an aid to intuition, one might consider a simple scenario in which we were attempting to discriminate between just two classes. Informally speaking, if a single discriminant function were used, it would be chosen so that it took a high (and roughly constant) value on samples from one class and a low (and roughly constant) value on samples from the other (as far as was possible).
The results are illustrated in Figure 1 and Table 2 . These show that by using just three linear discriminant vectors based on the full panel of genes, we are able to differentiate normal squamous esophagus tissue obtained from the BE and EA group (histologies 1 and 3) from the other histologies, but not from each other. Importantly, using the full panel of genes, we were able to identify adenocarcinomas with an error rate of only 20%. This result is striking because by simply classifying samples into histologies at random we would expect an error rate of approximately 80%.
The issue of over-fitting is relevant here. Informally speaking, with so many genes, one might expect to classify anything with reasonable success. More formally, our linear discriminants may be unstable due to the relatively high number of variables (genes) we are using to categorize the samples. Consequently, as is common in such applications, we assess the success of the discriminant analysis by performing a cross-validation study (Dudoit et al., 2002) . To do this, we reanalyse the data set after having removed one of the samples. We find the linear discriminants for the reduced data set and then use these discriminants to predict the histology of the removed sample. We perform this procedure once for each sample we might remove.
The results are shown in Table 3 and verify that we are able to predict adenocarcinoma of the esophagus with an error rate of only 25% using the full panel of genes, again with an expected error rate of 80% if the histologies were assigned at random.
Owing to the potential clinical importance of expression markers that are reliably either present or absent in Barrett's adenocarcinoma but not in premalignant Barrett's tissues, we sought to differentiate between the histologies of Barrett's esophagus and adenocarcinoma. We started by performing a LDA using the full panel of genes. The results of the LDA and the corresponding cross-validation are shown in Tables 4 and 5. The possibility that some of the genes add only noise to our results inspired us to perform a sequential logistic regression analysis in order to detect the genes which most powerfully distinguish between Barrett's esophagus and adenocarcinoma of the esophagus. Interestingly, the logistic regression analysis revealed a combination of only three genes (BFT, TSPAN, TP) to be the most powerful combination. We performed an LDA using just these three genes to discriminate between Barrett's esophagus and Barrett's associated adenocarcinoma. The cross-validation results for this study are listed in Table 6 and show that we were able to predict adenocarcinomas of the esophagus with an error rate of 0%. Figure 1 (a-c) Three two-dimensional representations of threedimensional data from a LDA considering all histologies and using the full panel of genes. Points are labelled according to their histological type. The axes correspond to the first three linear discriminant vectors. Histologies: 1.00 ¼ normal squamous esophagus from patients with Barrett's esophagus (BE group); 2.00 ¼ Barrett's esophagus from patients with Barrett's esophagus (BE group); 3.00 ¼ normal squamous esophagus from patients with esophageal adenocarcinoma (EA group); 4.00: Barrett's esophagus from patients with esophageal adenocarcinoma (EA group); 5.00 ¼ Barrett's associated adenocarcinoma
Permutation test
We performed a permutation test to examine whether our results might be a consequence of over-fitting of the data. For example, the results of the permutation test corresponding to the data shown in Tables 2 and 3 are illustrated in Figure 2 . Firstly, we created 50 data sets by using the old data on the full set of genes for all histologies and randomly permuting the histologies. Thus, each of the 50 new data sets has a different (randomly permuted) list of histologies, but the number of histologies of each type is constant across the data sets. We then performed an LDA on the permuted data sets and compared the results to that which we got when performing an identical analysis on the original data. If our original results were due to over-fitting, we would expect to do about as well when we performed the discriminant analysis on the permuted data sets as we did on the original data. As shown in Figure 2 , the average classification error rate is 46% when fitting the original data and 81% for the subsequent cross-validation study. This compares to error rates of 28% (red line in Figure 2 ) for the corresponding analysis in Table 2 , and 42% the cross-validation study in Table 3 . None of the error rates in the permuted data were close to the values seen in the real data. The smallest error rate seen during the crossvalidation tests for the permutated data was 68%, for example. These results fit with intuition. For randomly permuted data, there should be no relationship between histology and gene expression, and thus there should be no predictive power when attempting to assign a histology to the single, removed sample. Since we have five histologies, this essentially random prediction of histology for the removed sample results in an error rate of 80% in the cross-validation study, as per the above results. Consequently, we regard our observed crossvalidation error rate of 42% as clear evidence of the existence of a strong signal in our data. Since the effectiveness of any analysis is somewhat dependent on the assumptions made, we tried two other analysis techniques that have recently proven popular in the literature: Neural Nets and Multinomial regression. We conducted a cross-validation study for both analyses. In both cases, the degree of fit was comparable with, but slightly worser than that produced by the LDA (unpublished results).
Discussion
Most previous gene expression studies on Barrett's esophagus and esophageal adenocarcinoma have included only one or a few genes. Although these studies identified some important genes involved in this disease, the potential translational use of the findings is limited because of the wide variation in expression levels in the same histopathologic stage tissues from different individuals, and even, in some cases, a wide variation in different areas of the esophagus in the same individual . In an attempt to overcome these limitations, we measured the expression of a panel of 23 genes in different stages of Barrett's disease. Most of the genes studied have known association with gastrointestinal cancer, including esophageal adenocarcinoma in some cases: RARs , RXRs (Brabender et al., 2002a) , COX (Wilson et al., 1998) , DAPK (Cohen and Kimchi, 2001) , ODC (Brabender et al., 2001b), c-myb (Brabender et al., 2001a) , DPD (Terashima et al., 2002) , TP (Suda et al., 1999) , bcl2 (Woodward et al., 2000) , Bax (Woodward et al., 2000) , DNMT's (Eads et al., 1999) , and GSTPI (Brabender et al., 2002b) . The remaining genes were selected because they were highly differentially expressed in esophageal adenocarcinoma compared to normal esophagus in a previous microarray study (Scherf et al., 2001) .
The pattern of expression of many of the genes chosen was clearly different at different stages in the progression of Barrett's disease, with most of the differentially expressed genes having a pattern of either upregulation, downregulation, or an 'on-off' expression pattern with progression from normal squamous esophagus through the stages of premalignant Barrett's esophagus to esophageal adenocarcinoma. More than 9000 PCR reactions were performed, resulting in a quantity of data which, although small in comparison to that generated by many microarray studies, was nevertheless suitable for analysis using some of the bioinformatics methods employed for microarray data, such as LDA. LDA proceeds by finding linear combinations of the expression values for the genes, in such a way that the ratio of 'between histology' sum-of-squares to 'withinhistology' sum-of-squares is as large as possible. In simple terms, it aims to find linear combinations of genes that can differentiate between the histologies. Using LDA on the full panel of genes, we were reassuringly able to differentiate normal squamous esophagus tissues from Barrett's and adenocarcinoma tissues, but normal esophagus specimens obtained from patients with Barrett's esophagus and from patients with esophageal adenocarcinoma could not be distinguished from each other. This result contrasts with previous findings that expression levels for some genes, for example, telomerase reverse transcriptase (hTERT) (Lord et al., 2000) , are significantly different in the normal esophagus of patients with cancer compared to the normal esophagus of patients with Barrett's esophagus without cancer, and suggests that the pathologic area, and not just the normal esophagus, must be biopsied in order to use expression quantitation for possible clinical decision-making.
A logistic regression analysis was performed in order to test the relative value of different genes in the panel and identify those with the most power to distinguish between the Barrett's esophagus and adenocarcinoma histopathologies. Interestingly, this analysis showed that some of the genes in the full panel add only noise to the Figure 2 Histogram of the error rates for 50 randomly permuted data sets. The average classification error rate was 48% for the randomly permuted data performed for the complete set of genes and all five histologies compared to an error rate of 28% for the original data (shown as a red line and Table 2) results. Indeed, a combination of only three very informative genes (BFT, TSPAN, TP) was found to be the most powerful combination for discriminating between Barrett's esophagus and Barrett's associated adenocarcinoma. Improving considerably on the results obtained using the full panel of 23 genes, the LDA and cross-validation study using these three most informative genes was able to perfectly predict adenocarcinomas of the esophagus (error rate of 0%, see Table 6 ). This result suggests that, in contrast to the perhaps natural assumption that medical applications of expression analysis will use the complete, or a very large, expression profile, an expression profile using relatively few genes may be both more informative and more suitable for clinical translation.
The histologic classification scheme of Barrett's lesions, which is based on somewhat subjective, nonquantitative evaluations of limited visual microscopic histologic data, may convey limited information regarding lesion biology. Thus, a more reliable and comprehensive method of distinguishing between these histologies would be clinically useful, as would a better way of discovering biomarkers of true cancer risk. To our knowledge, this is the first report applying bioinformatic tools combined with quantitative realtime PCR to discriminate between Barrett's lesions. The data herein suggest that subtle histologies can be distinguished using linear discriminant and logistic regression analyses based on a panel of gene expression data. In this respect, our approach may be complementary to histologic characterization. Previous studies on Barrett's esophagus disease have pointed out important molecular and histologic differences between different stage lesions (Brabender et al., 2001a (Brabender et al., , b, 2002b (Brabender et al., , 2003 Lord et al., 2000 Lord et al., , 2001 . Nevertheless, none of those differences has proven consistently capable of discriminating between different Barrett's histologies.
In conclusion, our results suggest that mRNA expression quantitation of a panel of highly selected genes has the potential to discriminate between premalignant and malignant Barrett's disease. Logistic regression and LDAs can be used to further identify, from the complete panel, gene subsets with the power to make these diagnostic distinctions. Prospective translational studies to determine the potential clinical value of this approach are warranted.
Materials and methods
Tissue samples for RT-PCR
In all, 98 tissue samples obtained at endoscopy or operation from 19 patients with Barrett's esophagus without adenocarcinoma (BE group) and 20 patients with Barrett's associated esophageal adenocarcinoma (EA group) were collected and immediately frozen in liquid nitrogen. Specimens were classified as intestinal metaplasia (IM) if IM but no dysplasia or cancer was present. Specimens were classified as dysplastic if either low-grade dysplasia (LGD) or high-grade dysplasia (HGD) was present. Dysplastic tissues were not divided into LGD or HGD groups because areas of LGD and HGD were commonly present in the same specimen. Using these criteria, the following tissues were analysed: Barrett's IM (n ¼ 16), Barrett's dysplasia (n ¼ 3) and matching normal squamous tissue (n ¼ 19) in the BE group, and Barrett's adenocarcinoma of the esophagus (n ¼ 20), Barrett's IM (n ¼ 5), Barrett's dysplasia (n ¼ 15), and matching normal squamous esophagus tissues (n ¼ 20) in the EA group, for a total of 98 specimens. There were 30 men and 19 women, with a median age of 61.8 years (range 24-78 years). Endoscopic biopsies were obtained according to a protocol that required biopsy at 2 cm intervals from each quadrant (anterior, posterior, right, and left lateral positions) of the visible length of Barrett's mucosa and an additional biopsy from the normal appearing squamous mucosa of the esophagus. Normal esophagus biopsies were taken at least 4 cm proximal to the macroscopically abnormal epithelium. Part of the specimen or an adjacent specimen was fixed in formalin and paraffin for histopathological examination.
RNA extraction and cDNA synthesis
Total RNA was isolated by a single-step guanidinium isothiocyanate method using the QuickPreptMicro mRNA Purification Kit (Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA) according to the manufacturer's instructions, and cDNAs were prepared as described previously (Chomczynski and Sacchi, 1987; Lord et al., 2000) .
PCR quantification of mRNA expression cDNA quantitation of the 23 genes of interest and the internal reference gene (b-actin) was done using a fluorescence detection method (ABI PRISM 7700 Sequence Detection System, (TaqMan s ) Applied Biosystems, Foster City, CA, USA), as described (Gibson et al., 1996; Heid et al., 1996; Lord et al., 2000; Brabender et al., 2001b) .
The PCR reaction mixture consisted of 600 nM of each primer, 200 nM probe, 5 U AmpliTaq Gold Polymerase, 200 mM each dATP, dCTP, dGTP, 400 mM dUTP, 5.5 mM MgCl 2 , and 1 Â Taqman Buffer A containing a reference dye, to a final volume of 25 ml (all reagents Perkin-Elmer (PE) Applied Biosystems, Foster City, CA, USA). Thermal cycling was initiated with a denaturation step of 501C for 10 s and 951C for 10 min. The thermal profile for the PCR was 951C for 15 s and 601C for 1 min. Data obtained during 46 cycles of amplification were analysed. The primers and probes used are listed in Table 7 . Parallel TaqMan s PCR reactions were independently performed for each gene and the b-actin reference gene for each sample. All samples were analysed with the full panel of genes and each reaction was at least repeated once. The ratio between the values obtained was used as a measure for the relative mRNA expression.
Statistical analysis
Taqman s analyses yield values that are expressed as ratios between two absolute measurements (gene of interest/internal reference gene). Gene expression levels in adenocarcinoma, Barrett's esophagus, and normal squamous esophagus tissues were compared using the Kruskal-Wallis test to identify significant differences in expressions among the histopathologic groups. The Kruskal-Wallis test was also used to compare the three groups of normal esophagus tissues. When the overall Kruskal-Wallis test (comparing three groups) was significant at the 0.05 level, pairwise comparisons were based on the Mann-Whitney test and the nominal P-value was reported. The Wilcoxon signed rank test was used for comparison of paired tissues. Statistical significance (with Three primers are used in every reaction: two locus-specific PCR primers are flanking an oligonucleotide probe with a 5 0 fluorescent reporter dye (6-FAM) and a 3 0 quencher dye (TAMRA) two-sided tests) was set at the 0.05 level. LDAs and logistic regression analyses were performed to find genes or combination of genes that have the power to discriminate between different histologies. Cross-validation studies were performed to assess the success of the LDA (Dudoit et al., 2002) . To further guard against the issue of over-fitting the data, we performed a permutation test in order to assess the significance of our findings. The tissues were classified for the statistical analysis into the following groups: 1 ¼ normal squamous esophagus from patients with Barrett's esophagus (BE group); 2 ¼ Barrett's esophagus from patients with Barrett's esophagus (BE group); 3 ¼ normal squamous esophagus from patients with esophageal adenocarcinoma (EA group); 4 ¼ Barrett's esophagus from patients with esophageal adenocarcinoma (EA group); 5 ¼ Barrett's associated adenocarcinoma. The laboratory and statistical analyses were both performed in a blinded fashion. The statistician was unaware, for example, that histologies 1 and 3 were both normal esophagus.
